127 related articles for article (PubMed ID: 1677201)
1. Anatomical localization of the binding and functional characterization of responses to dopexamine hydrochloride in the rat mesenteric vasculature.
Amenta F; Ricci A; Napoleone P; Vyas SJ; Lokhandwala MF
Pharmacology; 1991; 42(4):211-22. PubMed ID: 1677201
[TBL] [Abstract][Full Text] [Related]
2. Biochemical, autoradiographic and pharmacological evidence for the involvement of tubular DA-1 receptors in the natriuretic response to dopexamine hydrochloride.
Vyas SJ; Apparsundaram S; Ricci A; Amenta F; Lokhandwala MF
Naunyn Schmiedebergs Arch Pharmacol; 1991 Jan; 343(1):21-30. PubMed ID: 1674360
[TBL] [Abstract][Full Text] [Related]
3. Dopexamine hydrochloride in the human heart: receptor binding and effects on cAMP generation.
Napoleone P; Ricci A; Ferrante F; Amenta F
Eur Heart J; 1992 Dec; 13(12):1709-17. PubMed ID: 1363232
[TBL] [Abstract][Full Text] [Related]
4. [Dopexamine: a new dopaminergic agonist].
Perrin G; Papazian L; Martin C
Ann Fr Anesth Reanim; 1993; 12(3):308-20. PubMed ID: 7902685
[TBL] [Abstract][Full Text] [Related]
5. Comparison of effects of dopamine hydrochloride and dopexamine hydrochloride on abdominal and femoral hemodynamics in anesthetized dogs.
van Kesteren RG; Heethaar RM; Charbon GA; Heethaar J; Brouwer FA
Circ Shock; 1993 Jul; 40(3):227-33. PubMed ID: 8348685
[TBL] [Abstract][Full Text] [Related]
6. The cardiovascular actions of dopexamine hydrochloride, an agonist at dopamine receptors and beta 2-adrenoceptors in the dog.
Smith GW; Hall JC; Farmer JB; Simpson WT
J Pharm Pharmacol; 1987 Aug; 39(8):636-41. PubMed ID: 2888855
[TBL] [Abstract][Full Text] [Related]
7. Cultured mesenteric vascular smooth muscle cells express dopamine DA1-receptors.
Balmforth AJ; Lyall F; Morton JI; Ball SG
Eur J Pharmacol; 1988 Oct; 155(3):305-8. PubMed ID: 2853067
[TBL] [Abstract][Full Text] [Related]
8. Dopexamine hydrochloride in the human kidney: localization, receptor binding and effect on 3'-5'-cyclic adenosine monophosphate generation.
Napoleone P; Cavallotti C; Ricci A; Amenta F
Nephron; 1993; 65(3):385-91. PubMed ID: 7904730
[TBL] [Abstract][Full Text] [Related]
9. IP66 (1[2-ethoxy-2-(3'-pyridyl)ethyl]-4-(2'-methoxy-phenyl)piperazine) enhances beta-adrenoceptor-induced vasodilatation in rat mesenteric vascular bed.
Perretti F; Nediani C; Manzini S
Arch Int Pharmacodyn Ther; 1990; 306():87-99. PubMed ID: 1963768
[TBL] [Abstract][Full Text] [Related]
10. Contrasting effects of dopexamine hydrochloride on electrolyte excretion in canine kidney.
Bass AS
J Pharmacol Exp Ther; 1990 May; 253(2):798-802. PubMed ID: 1971021
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the effects of dopexamine, a novel DA1 receptor and beta 2-adrenoceptor agonist, on cardiac function and splanchnic circulation in a canine model of hemorrhagic shock.
Chintala MS; Moore RJ; Lokhandwala MF; Jandhyala BS
Naunyn Schmiedebergs Arch Pharmacol; 1993 Mar; 347(3):296-300. PubMed ID: 8097568
[TBL] [Abstract][Full Text] [Related]
12. Dopexamine: a novel agonist at peripheral dopamine receptors and beta 2-adrenoceptors.
Brown RA; Dixon J; Farmer JB; Hall JC; Humphries RG; Ince F; O'Connor SE; Simpson WT; Smith GW
Br J Pharmacol; 1985 Jul; 85(3):599-608. PubMed ID: 2862944
[TBL] [Abstract][Full Text] [Related]
13. Presynaptic effects of dopexamine hydrochloride in the canine kidney.
Bass AS
Naunyn Schmiedebergs Arch Pharmacol; 1992 Jan; 345(1):33-6. PubMed ID: 1347154
[TBL] [Abstract][Full Text] [Related]
14. The effects of dopexamine on the cardiovascular system of the dog.
Brown RA; Farmer JB; Hall JC; Humphries RG; O'Connor SE; Smith GW
Br J Pharmacol; 1985 Jul; 85(3):609-19. PubMed ID: 4027482
[TBL] [Abstract][Full Text] [Related]
15. Pathogenesis of arterial lesions induced by dopaminergic compounds in the rat.
Kerns WD; Arena E; Macia RA; Bugelski PJ; Matthews WD; Morgan DG
Toxicol Pathol; 1989; 17(1 Pt 2):203-13. PubMed ID: 2568682
[TBL] [Abstract][Full Text] [Related]
16. Reduced effects of dopexamine on force of contraction in the failing human heart despite preserved beta 2-adrenoceptor subpopulation.
Böhm M; Pieske B; Schnabel P; Schwinger R; Kemkes B; Klövekorn WP; Erdmann E
J Cardiovasc Pharmacol; 1989 Oct; 14(4):549-59. PubMed ID: 2478768
[TBL] [Abstract][Full Text] [Related]
17. Renal vasodilatation by dopexamine and fenoldopam due to alpha 1-adrenoceptor blockade.
Martin SW; Broadley KJ
Br J Pharmacol; 1995 May; 115(2):349-55. PubMed ID: 7670737
[TBL] [Abstract][Full Text] [Related]
18. Studies on the pharmacological interventions to prevent oxygen free radical (OFR)-mediated toxicity; effects of dopexamine, a DA1 receptor and beta 2 adrenoceptor agonist.
Jacinto SM; Lokhandwala MF; Jandhyala BS
Naunyn Schmiedebergs Arch Pharmacol; 1994 Sep; 350(3):277-83. PubMed ID: 7824044
[TBL] [Abstract][Full Text] [Related]
19. Relative significance of dopamine receptors, beta adrenoceptors and norepinephrine uptake inhibition in the cardiovascular actions of dopexamine hydrochloride.
Goldberg LI; Bass AS
Am J Cardiol; 1988 Aug; 62(5):37C-40C. PubMed ID: 2841837
[TBL] [Abstract][Full Text] [Related]
20. Dopexamine hydrochloride. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in acute cardiac insufficiency.
Fitton A; Benfield P
Drugs; 1990 Feb; 39(2):308-30. PubMed ID: 1970288
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
